Published: Dec 30, 2021
Recently, the Indonesian information portal SUARA.COM,
Netherlands The World News and other media released news: 12.4 million doses of
adenovirus vector COVID-19 vaccine (KCONECAVAC) manufactured by Shenzhen
Kangtai Biological Products Co., Ltd. arrived in Indonesia.
Up to now, more than 30 million doses of adenovirus vector
COVID-19 vaccine (KCONECAVAC) have been exported to Indonesia, which is the
largest export order among similar vaccine varieties (adenovirus vector
COVID-19) in China.
On October 31, as reported by Indonesian National Agency of Drug
and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for
COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen
Kangtai Biological Products Co., Ltd.. It is understood that this is China's
second adenovirus vector COVID-19 vaccine approved for emergency use overseas.
Another vaccine, inactivated COVID-19 vaccine (KCONVAC), manufactured by
Shenzhen Kangtai Biological Products Co., Ltd. was approved for EUA in China in
May 2021. So BioKangtai has become the only vaccine enterprise in the world
that has two different vaccines at the same time.
According to the laboratory research of Oxford University *,
neutralizing antibody levels against Omicron following a third dose boost of
Vaxzevria were broadly similar to levels achieved after two doses against the
Delta variant. One booster dose of adenovirus vector vaccine is vaccinated 6
months after the completion of basic immunization (2 doses), and the antibody
level could be increased 6 times.
(PR Newswire, Shenzhen, December 30, 2021)
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
With global push for COVID-19 vaccines, China aims to win friends and cut deals